News
Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting
Novocure (NASDAQ: NVCR) today announced that research on Tumor Treating Fields (TTFields) therapy, including new data from the phase 2 2-THE-TOP trial and real-world evidence from patients
Savara Reports Third Quarter Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2023
Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous
Inogen to Present at Upcoming Investor Conferences in November 2023
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that management will present at the following
Acadia Healthcare to Participate in November Conferences
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in two conferences in November.
On Tuesday, November 14, 2023, the Company will participate in
LivaNova to Present at the Piper Sandler Healthcare Conference
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Bill Kozy, Interim Chief Executive Officer and Board Chair of LivaNova, will present in a fireside chat at
Humana Healthy Horizons partners with the Alzheimer’s Association to educate and support Floridians
Humana Healthy Horizons, the Medicaid business of leading health and well-being company Humana Inc. (NYSE: HUM), is forging a path to better outcomes for those impacted by Alzheimer’s Disease and
NanoString to Webcast Presentations from Upcoming Healthcare Conferences
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast
Savara to Present at the Jefferies London Healthcare Conference
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the
Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2023
Regulatory News:
POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Vistagen to Present at Stifel 2023 Healthcare Conference
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous
ISoP New Board of Trustees Members Announced
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, announced today that Amparo de la Peña, Vice
ICON plc to Present at Upcoming Investor Conferences
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organization powered by healthcare intelligence, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the Jefferies
Historic Victory as People With Diabetes Win Access to Life-Changing Technology, But Almost Half Don’t Understand the Benefits1-2
DexCom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today new market research which found 79% of people struggle to
Historic Victory as People With Diabetes Win Access to Life-Changing Technology, But Almost Half Don’t Understand the Benefits1-2
DexCom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today new market research which found 79% of people struggle to
Xencor Reports Third Quarter 2023 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today
Xencor Sells Portion of Royalties and Milestones from Ultomiris® and Monjuvi® to OMERS Life Sciences for $215 Million
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the sale
Inogen Announces Third Quarter 2023 Financial Results
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended September
Transgene Reports Business Update and Q3 2023 Financial Position
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its business update and its
Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), announced today the presentation of five studies (one oral and four posters) at the annual American College of Rheumatology
Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific Conferences
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous
Premier, Inc. Reports Fiscal-Year 2024 First-Quarter Results
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today reported financial results for the fiscal year 2024 first quarter ended September 30, 2023.
"Our
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on November 1, 2023, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement
NanoString Technologies Releases Operating Results for Third Quarter of 2023
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the third quarter ended
Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds
